Our findings suggest that CKS2‐shRNA may serve as a sensitizer to enhance the sensitivity of tumor cells to chemotherapy drugs, providing experimental evidence for potential clinical applications in BL and DLBCL. This evidence concerns the gene CKS2 and neoplasm.